GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Rating of "Moderate Buy" from Analysts

Market Beat
2025.04.28 06:32
portai
I'm PortAI, I can summarize articles.

GoodRx Holdings, Inc. (NASDAQ:GDRX) has received a consensus rating of "Moderate Buy" from eleven analysts. The average one-year price target is $7.93, with four analysts recommending a hold, six a buy, and one a strong buy. Recent price target adjustments include Wells Fargo lowering it from $9.00 to $8.00, Citigroup from $7.00 to $6.25, and KeyCorp from $7.00 to $6.00. The stock opened at $4.68, with a market cap of $1.80 billion and a 12-month range of $3.82 to $9.26.

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have received an average recommendation of "Moderate Buy" from the eleven ratings firms that are presently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $7.93.

  • Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

Several analysts recently commented on the company. Wells Fargo & Company cut their price objective on GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Citigroup cut their price target on GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a research note on Friday, January 10th. KeyCorp lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Finally, Truist Financial cut their target price on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research report on Thursday, April 10th.

Read Our Latest Report on GDRX

Institutional Investors Weigh In On GoodRx

  • This healthcare stock making a buzz with 160% growth

Institutional investors have recently bought and sold shares of the business. Barclays PLC lifted its position in shares of GoodRx by 1,316.1% in the third quarter. Barclays PLC now owns 140,113 shares of the company's stock valued at $973,000 after acquiring an additional 130,219 shares in the last quarter. Geode Capital Management LLC raised its stake in GoodRx by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 982,729 shares of the company's stock valued at $6,823,000 after purchasing an additional 58,610 shares during the period. Sanctuary Advisors LLC purchased a new position in GoodRx in the 3rd quarter worth approximately $85,000. Franklin Resources Inc. bought a new position in GoodRx in the 3rd quarter worth approximately $5,675,000. Finally, JPMorgan Chase & Co. grew its holdings in GoodRx by 358.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company's stock valued at $169,000 after buying an additional 18,997 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.

GoodRx Trading Down 2.5 %

NASDAQ:GDRX opened at $4.68 on Friday. The company has a market cap of $1.80 billion, a PE ratio of -156.00, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a 50 day simple moving average of $4.58 and a two-hundred day simple moving average of $4.91. GoodRx has a 12 month low of $3.82 and a 12 month high of $9.26.

About GoodRx

(Get Free Report
  • Gene therapy: Why does it cost millions for a single treatment?

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

See Also

  • Five stocks we like better than GoodRx
  • Dividend Screener: How to Evaluate Dividend Stocks Before Buying
  • Short Sellers Gave Up on These 3 Names Recently
  • Find and Profitably Trade Stocks at 52-Week Lows
  • 3 Boring Stocks Outperforming the Market This Year
  • 3 Natural Gas Stocks That Offer Great Dividend Yields
  • If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GoodRx Right Now?

Before you consider GoodRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.

While GoodRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.